Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]
Discontinued
Reference number: GID-TA10018
The Appraisal Committee was due to meet on 15 November 2016 to discuss cediranib for treating relapsed, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer. The company has notified that they have withdrawn their MA application in Europe for cediranib. Consequently, NICE will suspend the appraisal. The discussion of this appraisal at the committee meeting on the date above has been cancelled.